Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Banco de datos
Tipo del documento
Asunto de la revista
País de afiliación
Intervalo de año de publicación
1.
BMC Nephrol ; 15: 167, 2014 Oct 15.
Artículo en Inglés | MEDLINE | ID: mdl-25319344

RESUMEN

BACKGROUND: Early graft thrombosis and bleeding complications remain important causes of early graft loss following kidney transplantation in patients with antiphospholipid syndrome. Anti-ß2-glycoprotein I IgG is a disease-specific antibody in patients with antiphospholipid syndrome. Although plasmapheresis is partially effective for antibody removal, the optimal treatment allowing successful transplantation in patients with antiphospholipid syndrome has not been established. This is the first report of a patient with antiphospholipid syndrome who successfully underwent living-donor kidney transplantation following prophylactic plasmapheresis for removal of anti-ß2-glycoprotein I IgG. CASE PRESENTATION: A 37-year-old Japanese female was scheduled to undergo a living-donor kidney transplant from her mother. At age 25 years, she experienced renal vein thrombosis, was diagnosed with antiphospholipid syndrome secondary to systemic lupus erythematosus, and was subsequently treated with prednisolone and warfarin. At age 37 years, she was diagnosed with end stage kidney disease, requiring maintenance hemodialysis because of recurrent renal vein thrombosis despite taking anticoagulation therapy. The pretreatment protocol consisted of prophylactic plasmapheresis plus full anticoagulation therapy to counteract the risks of early graft thrombosis. Anticardiolipin and anti-ß2-glycoprotein I IgGs were successfully removed by both double filtration plasmapheresis and plasma exchange. The allograft kidney began to function soon after transplantation. No obvious thrombotic complications were observed after transplantation, although anti-ß2-glycoprotein I IgG increased to the level observed before plasmapheresis. One year after transplantation, the patient's kidney function remains stable while receiving anticoagulation therapy as well as a maintenance immunosuppressive regimen. CONCLUSION: Prophylactic plasmapheresis plus full anticoagulation therapy may be an effective strategy in patients with antiphospholipid syndrome undergoing living-donor kidney transplantation.


Asunto(s)
Síndrome Antifosfolípido/terapia , Fallo Renal Crónico/etiología , Trasplante de Riñón , Lupus Eritematoso Sistémico/complicaciones , Intercambio Plasmático , Plasmaféresis , Cuidados Preoperatorios/métodos , Trombofilia/terapia , Trombosis/prevención & control , Corticoesteroides/uso terapéutico , Adulto , Anticoagulantes/uso terapéutico , Síndrome Antifosfolípido/etiología , Autoantígenos/inmunología , Femenino , Rechazo de Injerto/prevención & control , Humanos , Inmunoglobulina G/sangre , Inmunoglobulina G/inmunología , Inmunosupresores/uso terapéutico , Fallo Renal Crónico/cirugía , Donadores Vivos , Lupus Eritematoso Sistémico/tratamiento farmacológico , Diálisis Renal , Trombofilia/tratamiento farmacológico , Trombofilia/etiología , Warfarina/uso terapéutico , beta 2 Glicoproteína I/inmunología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA